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1. Introduction 
Diabetes as a major public health problem 
Diabetes is a chronic disease marked by uncontrolled blood glucose, 
which is the fifth leading cause of death by disease in the U.S [1]. Prevalence of 
diabetes in the general US population is steadily increasing with recent data 
indicating that 7.7% of adults have diagnosed diabetes and 5.1% is undiagnosed 
with diabetes [2]. Another 29.5% of the population is at risk of diabetes based on 
having pre-diabetes. Overall, approximately 40% of the U.S. population has 
some hyperglycemic condition [2]. Diabetes and its complications remain major 
causes of morbidity and mortality in the U.S. 
The effects of diabetes can have a life-long impact on patients. Diabetes is 
associated with higher rates of lost work time, disability, and premature mortality. 
People with diabetes are at higher risk for heart disease, blindness, kidney failure, 
extremity amputations, and other chronic conditions [1]. People with diabetes 
have higher use of hospital inpatient care, outpatient and physician office visits, 
emergency visits, nursing facility stays, home health visits, visits with other health 
professionals, and prescription drug and medical supply use than their peers 
without diabetes [3]. 
The economic impact of diabetes is extensive. A significant portion of 
health care expenditures is attributed to diabetes and its complications [3]. The 
national cost of diabetes has grown to $156 billion and will increase to $192 
billion by 2020 [1]. The actual future costs are likely to be higher than these 
projected amounts if the prevalence of diabetes continues to grow, which is 
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correlated to the growing problem of obesity. Because of these complications, 
diabetes exacts great personal and societal costs.  
With the prevalence of diabetes growing, one reason behind it is the 
lifestyle that Americans live. With many not understanding or knowing what is 
involved in leading a healthy, nutritious lifestyle; that ultimately impacts causing 
unhealthy eating and living habits. Diabetes can lead to serious complications 
and premature death, but people with diabetes can take steps to control the 
disease and lower the risk of complications. 
Type 2 diabetes mellitus is a progressive and complex disorder that is 
difficult to manage effectively.  Majority of patients are overweight or obese at 
diagnosis and will be unable to achieve or sustain near normal glycemia without 
oral anti diabetic agents [6]; a sizeable proportion of patients will eventually 
require insulin therapy to maintain long-term glycemic control, either as mono-
therapy or in conjunction with oral anti-diabetic therapy.  The frequent need for 
escalating therapy is held to reflect progressive loss of islet β-cell function, 
usually in the presence of obesity-related insulin resistance. [4] 
Alpha-glucosidase inhibition for diabetes management 
Today's clinicians are presented with an extensive range of oral anti-
diabetic drugs for management of type 2 diabetes. The main classes are 
heterogeneous in their modes of action, safety profiles, and tolerability. 
According to the Anti-diabetic Agents Study, “These main classes include agents 
that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), 
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reduce hepatic glucose production (biguanides), delay digestion and intestinal 
absorption of carbohydrate, α-glucosidase inhibitors, (AGI’s) or improve insulin 
action (thiazolidinediones)” [4]. 
Digestion of dietary carbohydrates primarily occurs in the small intestine 
by α-amylase to yield both linear maltose and branched isomaltose 
oligosaccharides, neither of which can be absorbed into the bloodstream without 
further hydrolysis by α-glucosidases to release glucose.  Therefore, intestinal α-
glucosidases play a crucial role in controlling postprandial blood glucose. For this 
reason, one attractive prevention and/or treatment strategy for type-2 diabetes is 
the inhibition of α-glucosidase.  
The effectiveness of AGI’s for diabetes treatment is well documented in 
numerous animal and human clinical studies.  For instance, Acarbose has been 
shown to reduce postprandial serum glucose and insulin concentrations [5], 
improve metabolic control and produce a dose-dependent amelioration of 
diabetic nephropathy in the diabetic (db/db) mouse [6].  Acarbose also exerts 
beneficial effects on ischemia/reperfusion damage [7] and pancreatic islet 
damage by attenuating hyperglycemia [8].  In addition, it has been shown that α-
glucosidase inhibitor prevents age-related glucose intolerance [5] and improves 
insulin sensitivity in fructose-fed rats [9], thus, providing additional evidence for 
an anti-diabetic effect of α-glucosidase inhibitors.   
  Therefore, AGI’s have been used as anti-diabetic drugs to delay the 
breakdown of carbohydrate in the gut, and consequently slow the absorption of 
sugars, which will consequently lower postprandial insulin levels [10]. 
Alpha-glucosidase inhibitors and their side effects 
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Typical examples of current AGI’s are Acarbose, Miglitol, and Voglibose. 
They decrease both postprandial hyperglycemia and hyperinsulinemia, and 
thereby may improve sensitivity to insulin and release the stress on β-cells [11]. 
These compounds do not induce hypoglycemia and have a good safety profile, 
although gastrointestinal adverse effects may limit long-term compliance to 
therapy [10].  Acarbose is currently the only oral anti-diabetes agent approved for 
the treatment of both pre-diabetes and type 2 diabetes [12]. However, it has been 
associated with significant side effects. For instance, Acarbose is a 
pseudotetrasaccharide that inhibits intestinal α-glucosidase reversibly at the 
brush border of intestinal mucosa [13] as well as the pancreatic alpha amylase. 
Acarbose being a non-specific inhibitor, inhibits both α-glucosidase and α-
amylase. The inhibition of α-amylase produces serious gastrointestinal (GI) side 
effects, which can increase complications.  Pancreatic alpha-amylases hydrolyze 
complex starches to oligosaccharides in the lumen of the small intestine. These 
are then acted on by α-glucosidases and further degraded to glucose, which is 
absorbed into the blood-stream [14].  Inhibition of alpha-amylase results in large 
amount of undigested carbohydrates entering into the colon [15]. In the colon, 
bacteria digest the complex carbohydrates causing gastrointestinal side effects 
such as diarrhea, flatulence, abdominal discomfort, and bloating [16].  These 
symptoms are commonly observed and significantly restrict the use of AGIs. GI 
events caused a high rate of patient withdrawal in clinical trials involving these 
compounds [17]. In particular, the use of Acarbose has been associated with 
adverse GI side effects [10, 18] such as bloating, abdominal discomfort, diarrhea, 
and flatulence, which occur in about 20% of patients taking this drug [19].  With 
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respect to preventing type 2 diabetes, these potential side effects are of 
particular importance in medication used by persons with impaired glucose. 
Therefore, specific inhibitors of alpha-glucosidases are preferable in order to 
reduce GI side effects associated with current AGI’s that also inhibit alpha-
amylase.  
Grape Pomace   
In the past three decades, considerable research effort has been devoted 
to the discovery and development of novel active AGI’s since they are potential 
therapeutic agents for diabetes.  A variety of natural compounds and extracts 
have already been identified as being beneficial in the treatment of diabetes [20-
25].  In particular, phenolic compounds found in plants (i.e. tea, raspberries, 
strawberries, blueberries, and blackcurrants) have been found to be involved in 
the inhibition of α-glucosidase [26, 27].  For instance, green tea extract has been 
shown to inhibit rat intestinal α-glucosidases with an IC50 of 0.735mg/ml [25].  
The oral administration of green tea extract (300mg/kg bw for 4 weeks) 
remarkably reduced the fasting blood glucose (by 54%) in STZ-induced diabetic 
rats [28].  A procyanidins-rich pine bark extract (Pycnogenol®) was recently 
shown to potentially inhibit α-glucosidases, which has been associated with its 
anti-diabetic effect in patients with type 2 diabetes [20, 29].  A group of natural 
acylated anthocyanins also show α-glucosidase inhibitory activity [26].  
Grape pomace extract (GPE) was recently reported to selectively inhibit 
alpha-glucosidases without inhibiting alpha-amylase, leading to inhibition of 
postprandial hyperglycemia in diabetic animals [30], suggesting that grape 
pomace components may have a novel anti-diabetic effect.  
6 
  - -  
Grape, Vitis vinifera, is one of the most popular and widely cultivated fruits 
in the world. Grape contains several active components including flavonoids, 
polyphenols, anthocyanins, proanthocyanidins, procyanidins, and the stilbene 
derivatives resveratrol [31]. There is growing interests on phenolic compounds 
found within grapes focusing on their biological activities linking to human health 
benefits such as antioxidant, cardio-protective, anticancer, anti-inflammation, 
anti-aging and antimicrobial properties [31].   
These bioactive components of grape mainly exist in grape skin and 
seeds. Grape pomace, which is made up of the skins, seeds and stems are 
discarded during winemaking [32]. These wastes contain bioactive components 
with potent antioxidant and free radical scavenging activity. These chemical 
compounds have been linked to various health benefits. GPE and components 
have been widely studied for their antioxidant and other health-promoting 
properties [17]. However, very few studies have investigated the potential of 
grape pomace as an alternative bio-resource for diabetes management [30]. 
Currently the only research, conducted by our laboratory has reported that GPE 
has an inhibitory activity, exerting a significant anti-postprandial hyperglycemic 
effect, suggesting that grape pomace could be a valuable food derived bio-
resource that is rich in antioxidants and anti-hyperglycemic compounds [30].  
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2. Objectives of this Study 
Our long-term goal is to develop a potential dietary intervention for diabetes 
management from GPE.  The specific objective of this research is to prepare 
more effective GPE by fractionating and isolating active compounds that inhibit 
alpha-glucosidases in a specific GPE. The data obtained from this study will help 
identify the perimeters/ conditions that optimize the preparation of GPE and its 
components will lead to future animal and/or human studies to further determine 
their potential in preventing and treating Type-2 diabetes.    
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3. Materials and Methods 
Materials and reagents 
Yeast type I α-glucosidase (EC 3.2.1.20, G5003), rat intestinal acetone 
powder (N1377-5G), p-nitrophenyl α-D-glucoside (pNPG), silica gel and C-18 
were all purchased from the Sigma Chemical Co. (St. Louis, MO, USA). 
Acarbose (A0802) was purchased from LKT Laboratories Inc,(St. Paul, MN).The 
HTS 7000 Bio Assay Reader was acquired from MTX Lab Systems Inc Plate, 
Perkin Elmer (Norwalk, Ct). The BUCHI Roto-evaporator R-124 and water bath 
B-481was acquired from GoIndustry DoveBid, (Westbury, NY).The HPLC Hitachi 
Elite LaChrom Autosampler L-2200 was purchased from HITACHI, Japan. The 
glassware 45/50 Synthware, Chemglass 24/40 1000 ml were purchased from 
Fisher Scientific Co (Hampton, New Hampshire). The butanol, ethanol and 
methanol solvent was HPLC grade (Fisher Scientific Co.) 
 
Experimental protocols 
1. GPE preparation  
Air dried red grape pomace supplied Dr. John Parry at Virginia State 
University was grounded to fine powder. The powder (50g) was extracted with 
500 ml of 70% ethanol under stirring overnight.  The supernatant was filtered on 
a Büchner funnel and collected.  The supernatant was concentrated by the 
BUCHI Roto-evaporator (Westbury, NY).  The rotary evaporator was used to 
remove the organic solvents from the extract without excessive heating of the 
sample (set at 60°C). The concentrated GPE was collected and placed into a 
weighed vial. A small amount of methanol or ethanol was added to rinse and 
collect the residue. The concentrated GPE was placed under the hood to 
completely dry.  
2. GPE fractionation and purification 
9 
  - -  
2.1 Liquid-liquid separation  
The separatory funnel was used in liquid-liquid extractions to separate 
(partition) the components of a mixture between two immiscible solvent phases 
of different densities. The concentrated GPE was poured into a separator funnel 
then Butanol and water were added to the funnel. The funnel was vigorously 
inverted several times to mechanically mix up the two solvents. The funnel was 
settled for the phases to separate. If it was difficult to distinguish between the 
layers more butanol was added as needed. Butanol and water are incompatible 
so the water will settle at bottom. Once the layers are distinguished, water was 
released out of the funnel. The partition was repeated six more times to ensure a 
more thorough separation of compounds into butanol fraction.  
2.2 Open column chromatography  
 Column chromatography was used to separate compounds from the 
active fraction (identified by alpha-glucosidase assay) in. An open glass column 
(Chemglass 24x40) was used. Cotton was placed at the bottom of the column to 
prevent the stationary phase from being washed out. The column was originally 
packed using silica gel. Separation was unsatisfactory using this method. The 
column was then packed with 100mg of C18 (10 micron) via the dry method and 
activated with ethanol. The GPE fraction was reconstituted with 15% methanol 
and loaded into the column. It was eluted with aqueous methanol system. A 
range of ratios were used for the column: 30% MEOH 70% H20, 50% MEOH 
50 % H20, and 70% MEOH 30 % H20. 
 Twenty fractions were collected based on different affinity between 
stationary and mobile phases, all listed in Figure 1. All the collected fractions 
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were subjected to thin layer chromatography test and those with the same 
components were combined for alpha-glucosidase assay.  
2.3 Thin layer chromatography (TLC) 
TLC was performed to determine whether the fractions collected were 
different or the same. After comparison, fractions with a similar pattern were 
combined.  Thin layer chromatography was performed on a sheet of aluminum 
foil coated with a thin layer of absorbent material usually silica gel. This layer of 
adsorbent is known as the stationary phase. A portion of the fractions were 
dissolved in methanol and a small drop was placed on the base line of the plate 
about 1.5 cm from the bottom of the edge.  Allow the sample to completely dry 
using a blow-dryer.  A small amount of appropriate solvent; ethyl acetate, 
methanol, water in the ratio of 60/40/2 with 2 drops of acetic acid, was poured 
into a glass beaker. The TLC plate was placed into the beaker, making sure the 
spots of the sample don’t touch the solvent and the lid is closed. The solvent was 
drawn up the plate by capillary action. The mobile phase flowed through the 
stationary phase and carried The solvent was drawn up the plate by capillary 
action. The mobile phase flowed through the stationary phase and carries the 
components of the mixture with it.  the components of the mixture with it. When 
the solvent reaches no higher than top of the TLC plate, the plate was removed 
using tweezers. The TLC plate was placed on the side to dry. Different 
components traveled at different rates and the dried plate was scanned under UV 
light to detect spots that contain separated components.  
2.4 Rotary evaporation of GPE fractions  
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The fractions collected from open column chromatography with the same 
TLC pattern were combined and further concentrated using a BUCHI Rotary 
Evaporator R-124, (Westbury, NY). The concentrated fractions were then air-
dried in a fume hood and immediately stored in a -20°C freezer.  
3. Prepare reagents for enzyme assay 
Preparing stock and working solutions for enzymatic experiments: After all 
GPE fractions have been collected and completely dried, 2 mg of each fraction 
was placed into a small centrifuge tube and methanol was added to get a 
concentration of 2 mg/ml. Serial dilutions were made to prepare working GPE 
solutions  to test activity.  
3.1 Prepare Acarbose stock and working solution 
Ten mg of Acarbose was dissolved in 10 mL 0.1 M phosphate buffer (PB, 
pH 6.8) to achieve a 1 mg/mL stock solution. Fifty µL of above solution was 
mixed with 4.95 mL 0.1 M PB pH 6.8 to achieve a 10 µg/mL working solution. 
Use a vortex mixer to obtain a homogeneous mix 
3.2 Prepare substrate PNPG solutions in PB buffer 
P-nitrophenyl-α-d-glucopyranoside (pNPG) is a universe substrate of α-
glucosidases, which was used as the substrate for intestinal α-glucosidases in 
our experiments Sixty milligram of pNPG powder was dissolved in 50 mL 0.1 M 
PB pH 6.8 to achieve a 4 mM concentration.  
 
3.3 Prepare rat intestinal α-glucosidases  
Rat intestinal powder (2.5g) was suspended in 100 mL of 0.1 M PB (pH 
6.8). The suspension was shaken overnight and the supernatant was collected 
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upon centrifugation and filtration using 0.45 µm of coarse filter paper. For 
experiments, the dried enzyme extract was weighed and dissolved in 0.1 M PB 
pH 6.8 to achieve a 25mg/ mL concentration. 
4. Enzyme Assay  
One hundred µl of each sample was loaded into each well of the 96 well plate. 
One hundred µl of Acarbose (10 µg/mL) and solvent used to dissolve GPE (5% 
Methanol and 95% H20) were used as positive and negative controls. The 
reaction was initiated by the addition of 100 µl of α-glucosidase enzyme and 50 
µl of substrate (pNPG) into all wells. Absorbance readings of assay were 
recorded at 450nm with shaking using HTS 7000- Bio Assay Reader- Perkin 
Elmer (Norwalk, Ct). The α-glucosidase inhibitory activity was expressed as % 
inhibition. 
5. High performance liquid chromatography (HPLC) 
The HPLC (Hitachi, Schaumburg, IL) was used for the separation of the 
active fractions identified in the alpha-glucosidase assay for qualitative and 
quantitative analysis of potential active compounds. An analytical C18 (250x5mm) 
was used for separation and a diode array detector (DAD) was used to monitor 
fractions and compounds eluted from the column. Twenty mg of active fraction 
was dissolved in 2 ml methanol.  The solution was filtered via 0.45 µm of filter 
paper and placed in a vial.  A variety of mobile phases and programs (described 
below) were developed to optimize the separation. A gradient program was 
chosen since the isocratic separation was not satisfactory for separation. 
Methanol and water was used first for the mobile phase gradient. After series of 
tests, it was concluded that acetonitrile and water gradient method provided the 
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4. Results and Discussion 
Alpha-glucosidase inhibition by GPE and its fractions 
GPE has been identified as an inhibitor of α- glucosidase in our previous 
studies. Our goal was to identify active fractions or components in GPE.  The 
initial liquid-liquid partition of GPE led two fractions: water and butanol fractions.  
In our preliminary separation, we tried liquid-liquid separation into three phases: 
water, butanol, and ethyl acetate and found that the ethyl acetate fraction was 
the most effective fraction followed by the butanol fraction via the α -glucosidase 
assay. However, the ethyl acetate fraction contained very little amounts of 
compounds. In the following separation, we were only using water and butanol 
for partitioning. The butanol fraction was further subject to open column 
chromatography.  
Open column chromatography 
From the fractions assayed slight inhibition was recorded in sub fraction 1. 
The α-glucosidase inhibitory activity was expressed as % inhibition listed in 
Figure 2. In comparison to the other fractions from the column, fraction 1 had the 
highest inhibitory effects at 35% compared to the positive control 87.64% and 
negative control -.565% listed in Figure 3.  
HPLC analysis on the fraction 1 
Fraction 1 was further separated via HPLC to determine which 
compounds were within that fraction and more specifically, which compound 
possibly inhibited the enzyme alpha glucosidase. The sample was prepared and 
tested using a wide range of method systems and wavelengths. Methanol mixed 
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with water was first chosen as the mobile phase but displayed insufficient 
separation on C18 column since the peaks were crowded together. After a series 
of method development, we determined that the gradient system of acetonitrile 
(ACN) and water, wavelength 210 nm, and injection volume of 20 µl displayed 
optimal absorption and was used for collection of compounds. ACN was selected 
because it had low noise in UV detection and resulted in less ghost peaking for 
gradient baselines. The polarity is lower and it can interact with the molecules  to 
provide better peak separation. The HPLC chromatograms and methods are 
shown in Figures 4-8. 
Open column chromatography of GPE for scaling up 
As above showed, we have successfully isolated and collected two 
compounds (peaks) from the active fraction 1. However, the amounts of the 
compounds were too little (less than 0.2 mg) to conduct structure elucidation. In 
order to obtain a sufficient amount of the compounds for activity and structure 
analysis, we tried to develop an alternative fractionation and separation 
procedure that could allow for scaling up.  In this method development, GPE was 
recreated with the protocol slightly changed. The column was packed with Diaion 
Resin instead of C18. Diaion Resin (HP-20) was used because it has much 
larger sample capacity than C18 does. We collected the new fraction in hope of 
having a larger active sample amount for further testing. When the activity was 
tested on GPE using the assay there was no inhibition noticed in any of the 
fractions separated from the second column. Possible reasons why the second 
column produced no activity could be because the active compounds may work 
synergistically and they lose their activity once being fractionated by HP-20. The 
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method employing C18 is probably the best for purity of the fraction, but it would 
not be the best method quantitatively.  We further tried with an open column 
loaded with coarse C18 resin to separate GPE and collected over 30 fractions. 
However, none of these fractions exerts significant inhibition on alpha-
glucosidase.  
Other reasons why inhibition could have been affected  
 
   The butanol fraction of GPE displayed inhibition on rat intestinal alpha-
glucosidases. With the Grape pomace being mixed with other compounds this 
could have had a negative effect limiting its activity. The bioactivity of GPE could 
possibly be reduced once it is separated if the compounds have a synergistic 
effect. There is also a possibility of the fractions having an inhibitory effect for a 
limited amount of time. Subjecting the dried Grape Pomace to high temperatures, 
color extractions and distillation could have had a significant effect on the 
inhibitory activity of the alpha glucosidase enzyme. There is the possibility that 
concentrations could also be too low at this level and inhibition could not be 
observed. From this ongoing research there is activity noted in GPE but there 
could be many reasons to why it is difficult to notice higher levels of inhibition in 
the subsequent fractions of GPE. Fraction 1 showed significant inhibition of alpha 
glucosidase, but analyzing the results with the control, the absorbance levels 
were still low and not consistent enough to make a clear inference. 
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5. Conclusion 
 
We identified an active fraction (F1) from GPE, through open column and 
HPLC, which had inhibitory effects to alpha glucosidase. The further HPLC 
separation yielded two major peaks. The two major peaks were collected and will 
undergo future structure identification and elucidation. After structure 
identification and elucidation is complete; testing will be conducted to the 
compounds, using the bio-assay reader, identifying their activity. If the 
compounds are active we will continue with the method listed above. We have 
tried open column chromatography using HP20 and coarse C18 for scale-up of 
GPE separation but the resulting fraction failed to show significant inhibition on 
alpha-glucosidases. Further method development is needed if the collected 
peaks are not active compounds.  
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Figure 1- The process Grape pomace extract separation  
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Figure 2 - Percent Inhibition of Grape Pomace Fractions 
Percent inhibition of alpha- glucosidase from grape pomace fractions. Enzyme 
assay conducted with absorbance wavelength 450nm. F1 has the highest 
percent inhibition of 35% compared to other fractions.  Bars with different 
superscript values are significantly different from each other (p <0.05).  
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Figure 3
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Figure 3- Comparison of Percent Inhibition to control  
Enzyme assay conducted with wavelength 450nm. Percent inhibition of F1 
compared to Acarbose (positive control) and 5% methanol and 95 % water 
(negative control). F1 showed positive inhibitory effects when compared to the 
positive and negative controls. Bars with different superscripts/subscripts values 
are significantly different from each other (p <0.05).  
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Figure 5- Method 2  
A different method was employed using gradient system of methanol and water 
for HPLC testing. The chromatogram results still did not show possible 
compounds. The timing of the mobile phase needed to be down, to view the 
other compounds that could possibly be in the sample. Gradient systems were 
used as follows: 0-5 min 80% methanol, 20-23 min 100% methanol, 25-30 min 
80 % methanol.  
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Figure 6- Method 3 
This chromatogram was altered by increasing water in column to extend out the 
timing the peaks occurred. The time was also increased to observe the other 
possible compounds. Gradient systems were used as follows: 0-3min 10% 
methanol, 18-21min 30%methanol, 31-36 min 60% methanol, 46-50 min 95% 
methanol, 56-60 min 90% methanol.  
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Figure 7 
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Figure 7- Method 4 
ACN was introduced into the gradient system. The injection volume was 
increased to 30ul. Gradient systems were used as follows: 0-3min 10% 
acetonitrile, 18-21 min 30% acetonitrile, 31-36min 60% acetonitrile, 46-50 min 
95% acetonitrile 56-60min 90% acetonitrile.  
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Minutes
0 10 20 30 40 50 60
mA
U
0
200
400
600
800
1000
1200
mA
U
0
200
400
600
800
1000
1200
DAD-207 nm
Gayle20120626ACN_2
 
Figure 8- Method 5 
We determined that for separtion ACN was a preferable solvent to separate the 
fraction 1. The injection volume was reduced to 20µl because the original 
injection made the peak too high. This chromatogram provided better peaks and 
2 compounds were observed. We continued to adjust the method slightly to 
separate the peaks from each other and begin to collect the compound. Gradient 
systems were used as follows: 0-3 min 10% acetonitrile, 15-30 min 20% 
acetonitrile, 40-46 min 50% acetonitrile, 50 min 90 % acetonitrile, 54 min 95% 
acetonitrile, 57-60 min 90% acetonitrile.  
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Diabetes and its complications are steadily growing and remain major 
causes of morbidity and mortality in the U.S. Intestinal α-glucosidases play a 
crucial role in controlling postprandial blood glucose. For this reason, one 
attractive prevention and/or treatment strategy for type-2 diabetes is the inhibition 
of α-glucosidase. The effectiveness of α-glucosidase inhibitors (AGI’s) for 
diabetes treatment is well documented in numerous animal and human clinical 
studies.  Grape pomace extract (GPE) has recently found in our laboratory to 
selectively inhibit alpha-glucosidases without inhibiting alpha-amylase, leading to 
inhibition of postprandial hyperglycemia in diabetic animals. The present study 
was designed to identify effective GPE by fractionating and isolating active 
compounds that inhibit alpha-glucosidases in a specific GPE. From enzyme 
assay testing, results revealed Fraction 1 active,  showed 35% inhibition (p <0.05) 
compared to the positive control 87.64% and negative control -.565%. HPLC was 
conducted on F1, which yielded two potential active compounds (peaks) 
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following ACN gradient system method. F1 will undergo future structure 
identification and elucidation.  
 Fractionation of GPE yielded a very small amount of active F1 for testing. Open 
column chromatography using HP20 and coarse C18 for scale-up of GPE 
separation but the resulting fraction failed to show significant inhibition on alpha-
glucosidases. Further method development is needed if the collected peaks are 
not active compounds. 
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